The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

The following is a summary of "Determining the Impact of COVID-19 Infection on Patients Hospitalized With COPD Exacerbations: ...

The following is a summary of “Losing Your Breath During the Storm: Spontaneous Pneumothorax and Subcutaneous Emphysema as a ...

This deal combines Spire's patient monitoring technology with Wellinks' virtual-led cardiopulmonary care approach, creating ...

Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

Sleep apnoea devices giant ResMed has laid out an ambitious growth strategy aiming to broaden its product lines and notch up ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.

A team of doctors at CK Birla Hospital, Gurugram, successfully performed a complex surgery on a 34-year-old woman suffering ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...